Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anthracycline cardiotoxicity].

E Finolezzi1, C Torromeo, B Vincenzi

  • 1Libera Università Campus Biomedico, Via Emilio Longoni 83, 00155 Roma.

La Clinica Terapeutica
|July 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis.

Breast cancer research and treatment·2026
Same author

Activity of chemotherapy in mesenchymal chondrosarcoma: a multicentre retrospective analysis within the Italian Sarcoma Group network.

ESMO open·2026
Same author

Medical decision analysis for personalized oncology at the patient bedside.

Tumori·2026
Same author

Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma Group.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registry.

ESMO open·2024
Same author

Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study.

ESMO open·2024

Anthracycline chemotherapy can cause heart damage (cardiotoxicity). Early detection using bidimensional echocardiography is crucial for managing this risk, especially with cumulative doses over 550 mg/m2.

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Anthracyclines are vital chemotherapeutic agents.
  • Cardiotoxicity is a significant complication of anthracycline therapy.
  • Early detection and management are key to improving patient outcomes.

Purpose of the Study:

  • To review recent data on anthracycline-induced cardiotoxicity.
  • To discuss diagnostic methods for detecting cardiotoxicity.
  • To inform specialists and general practitioners on managing this complication.

Main Methods:

  • Literature review of MEDLINE and article references.
  • Focus on pathogenesis and diagnostic tools for cardiotoxicity.
  • Analysis of studies on anthracycline cardiotoxicity.

Related Experiment Videos

Main Results:

  • Cardiotoxicity presents in acute, chronic, and late patterns.
  • Bidimensional echocardiography is a cost-effective, sensitive, and specific diagnostic tool.
  • Endomyocardial biopsy and radionuclide angiocardiography are considered gold standards but less practical.

Conclusions:

  • Anthracycline cardiotoxicity is a major concern in cancer therapy.
  • Cumulative dose >550 mg/m2 is a primary risk factor.
  • Bidimensional echocardiography is the preferred method for evaluating anthracycline-related cardiotoxicity.